HemoSonics Honored as One of the Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500

DURHAM, N.C. – NOVEMBER 25, 2024 – HemoSonics, LLC, a medical device company focused on acute bleeding management, today announced it ranks #453 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech and energy tech companies in North America, which is now in its 30th year. The Deloitte Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2020 to 2023, during which time HemoSonics more than doubled its revenue. HemoSonics was one of eight North Carolina companies named to the Deloitte Fast 500 in North America. Deloitte honors less than 1% of the over 800,000 privately held companies in the US. A full list of the Deloitte Technology Fast 500 winners by state and category can be viewed here.

HemoSonics’ Quantra Hemostasis System consists of the Quantra Hemostasis Analyzer with QPlus and QStat Cartridges, which provide clinicians with information to inform patient-centered decisions on bleeding management that improve care and optimize blood product usage. The Quantra System uses innovative SEER Sonorheometry (Sonic Estimation of Elasticity via Resonance), a proprietary medical-grade ultrasound technology that measures the coagulation properties of a whole blood sample. Quantra provides fast, comprehensive whole-blood coagulation analysis at the point of care or in laboratory settings in less than 15 minutes.

HemoSonics’ Quantra System is FDA-cleared for cardiovascular surgery, trauma, liver transplantation, and major orthopedic surgery. It requires minimal resources to maintain, is easy to operate and interpret, and enables hospitals to standardize a clinically and operationally efficient viscoelastic testing program.

“Innovation is at the heart of what we do at HemoSonics, and we’re thrilled to be mentioned alongside companies of all industries who are changing the world for the better,” said Bob Roda, HemoSonics President and CEO. “Our technology positively impacts hospitals and patient outcomes, and recognition such as this helps drive our company forward in our pursuit of excellence and further innovation.”

To be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology sold to customers in products that contribute to most of the company’s operating revenues and have base-year operating revenues of at least $50,000 and current-year operating revenues of at least $5 million.

“For 30 years, we’ve been celebrating companies actively driving innovation. The software industry continues to be a beacon of growth, and the fintech industry made a strong showing on this year’s list, along with life sciences,” said Steve Fineberg, vice chair, U.S. technology sector leader at Deloitte. “Significantly, we also saw a breakthrough in the performance of private companies, with the highest number of private companies on the list in our program’s history. This year’s winners have shown they have the vision and expertise to continue performing at a high level, which deserves to be celebrated.”